A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anti-cancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis